NASDAQ:CRSP - Crispr Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$48.92 +0.25 (+0.51 %)
(As of 08/20/2018 04:00 PM ET)
Previous Close$48.67
Today's Range$48.06 - $49.77
52-Week Range$16.16 - $73.90
Volume413,700 shs
Average Volume1.27 million shs
Market Capitalization$2.24 billion
P/E Ratio-28.57
Dividend YieldN/A
Crispr Therapeutics logoCRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio17.89
Quick Ratio17.89


Trailing P/E Ratio-28.57
Forward P/E Ratio-16.93
P/E GrowthN/A

Sales & Book Value

Annual Sales$41 million
Price / Sales56.78
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book11.96


EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-245.57%
Return on Equity-39.58%
Return on Assets-28.49%


Outstanding Shares47,590,000
Market Cap$2.24 billion

Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

What is Crispr Therapeutics' stock symbol?

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How were Crispr Therapeutics' earnings last quarter?

Crispr Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.19. The company had revenue of $1.09 million for the quarter, compared to analyst estimates of $1.47 million. Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%. View Crispr Therapeutics' Earnings History.

When is Crispr Therapeutics' next earnings date?

Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Crispr Therapeutics.

What price target have analysts set for CRSP?

9 Wall Street analysts have issued 1-year price targets for Crispr Therapeutics' stock. Their predictions range from $51.00 to $86.00. On average, they expect Crispr Therapeutics' stock price to reach $65.1714 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.

What is the consensus analysts' recommendation for Crispr Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics.

What are Wall Street analysts saying about Crispr Therapeutics stock?

Here are some recent quotes from research analysts about Crispr Therapeutics stock:
  • 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (8/10/2018)
  • 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)

Who are some of Crispr Therapeutics' key competitors?

Who are Crispr Therapeutics' key executives?

Crispr Therapeutics' management team includes the folowing people:
  • Dr. Rodger Novak, Founder & Chairman (Age 51)
  • Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
  • Dr. N. Anthony Coles Jr., Sr. Advisor (Age 58)
  • Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)
  • Dr. Chad Cowan, Scientific Founder

When did Crispr Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Has Crispr Therapeutics been receiving favorable news coverage?

Media coverage about CRSP stock has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Crispr Therapeutics earned a coverage optimism score of -0.15 on Accern's scale. They also assigned media coverage about the company an impact score of 41.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Crispr Therapeutics.

Who are Crispr Therapeutics' major shareholders?

Crispr Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Versant Venture Management LLC (7.65%), NEA Management Company LLC (4.43%), Federated Investors Inc. PA (1.34%), BlackRock Inc. (1.26%), Orbimed Advisors LLC (1.04%) and ARK Investment Management LLC (0.99%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Simeon George, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Institutional Ownership Trends for Crispr Therapeutics.

Which major investors are selling Crispr Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Versant Venture Management LLC, Wells Fargo & Company MN, Global Thematic Partners LLC, Capital Advisors Inc. OK, First Allied Advisory Services Inc., CIBC World Markets Inc. and EAM Global Investors LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Insider Buying and Selling for Crispr Therapeutics.

Which major investors are buying Crispr Therapeutics stock?

CRSP stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, ARK Investment Management LLC, Orbimed Advisors LLC, FMR LLC, Renaissance Technologies LLC, First Trust Advisors LP, Casdin Capital LLC and Korea Investment CORP. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer, Corp /De/ Celgene and Simeon George. View Insider Buying and Selling for Crispr Therapeutics.

How do I buy shares of Crispr Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Crispr Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $48.92.

How big of a company is Crispr Therapeutics?

Crispr Therapeutics has a market capitalization of $2.24 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Crispr Therapeutics employs 127 workers across the globe.

How can I contact Crispr Therapeutics?

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.

MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel